4.6 Article

Inter-seasonal compressed-air energy storage using saline aquifers

Journal

NATURE ENERGY
Volume 4, Issue 2, Pages 131-139

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s41560-018-0311-0

Keywords

-

Funding

  1. Engineering and Physical Science Research Council (EPSRC) of the United Kingdom
  2. Energy Technology Partnership

Ask authors/readers for more resources

Meeting inter-seasonal fluctuations in electricity production or demand in a system dominated by renewable energy requires the cheap, reliable and accessible storage of energy on a scale that is currently challenging to achieve. Commercially mature compressed-air energy storage could be applied to porous rocks in sedimentary basins worldwide, where legacy data from hydrocarbon exploration are available, and if geographically close to renewable energy sources. Here we present a modelling approach to predict the potential for compressed-air energy storage in porous rocks. By combining this with an extensive geological database, we provide a regional assessment of this potential for the United Kingdom. We find the potential storage capacity is equivalent to approximately 160% of the United Kingdom's electricity consumption for January and February 2017 (77-96 TWh), with a roundtrip energy efficiency of 54-59%. This UK storage potential is achievable at costs in the range US$0.42-4.71kWh(-1).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

The diagnostic experience for people with MND and their caregivers in the UK

Mary R. O'Brien, Christopher McDermott, Samar Aoun, David Oliver, Jennifer A. Kirton

Summary: This study explores the perspectives of individuals diagnosed with MND and their family caregivers on the consultation process, diagnosis delivery, and adherence to the UK NICE MND guideline. A survey was conducted in 2018-19, with 69 MND patients and 39 caregivers participating. The results show that MND patients have higher satisfaction with their neurologist's skills and ability, but many of the guideline recommendations were not met. There is a need for greater awareness of the needs of MND patients and caregivers, as well as better promotion and resources for the NICE MND guideline.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2023)

Article Clinical Neurology

ALSUntangled #65: glucocorticoid corticosteroids

Jill Ann Goslinga, Mark Terrelonge, Richard Bedlack, Paul Barkhaus, Benjamin Barnes, Tulio Bertorini, Mark Bromberg, Gregory Carter, Amy Chen, Jesse Crayle, Mazen Dimachkie, Leanne Jiang, Gleb Levitsky, Isaac Lund, Sarah Martin, Christopher Mcdermott, Gary Pattee, Kaitlyn Pierce, Dylan Ratner, Lenka Slachtova, Yuyao Sun, Paul Wicks

Summary: This article reviews the evidence of glucocorticoids in ALS treatment and concludes that they do not provide clinical benefits and have serious risks.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2023)

Article Clinical Neurology

Prevalence of depression in amyotrophic lateral sclerosis/motor neuron disease: multi-attribute ascertainment and trajectories over 30 months

C. A. Young, J. Ealing, C. J. McDermott, T. L. Williams, A. Al-Chalabi, T. Majeed, K. Talbot, T. Harrower, C. Faull, A. Malaspina, J. Annadale, R. J. Mills, A. Tennant

Summary: This study reveals that the prevalence of depression in ALS patients is close to a quarter, with most patients belonging to a single trajectory group. Estimates based on screening for current depressive symptoms underestimate the actual prevalence of depression.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2023)

Review Clinical Neurology

ALSUntangled #67: rituximab

Xiaoyan Li, Carmel Armon, Paul Barkhaus, Benjamin Barnes, Michael Benatar, Tulio Bertorini, Mark Bromberg, Gregory T. Carter, Jesse Crayle, Merit Cudkowicz, Mazen Dimachkie, Eva L. Feldman, Jonathan Glass, Jill Goslinga, Terry Heiman-Patterson, Sartaj Jhooty, Rachel Lichtenstein, Isaac Lund, Christopher Mcdermott, Gary Pattee, Kaitlyn Pierce, Dylan Ratner, Kristiana Salmon, Paul Wicks, Richard Bedlack

Summary: ALSUntangled reviews alternative and off-label treatments for ALS and finds that rituximab, a drug depleting B lymphocytes, lacks evidence of efficacy in ALS. One patient's experience with rituximab showed no benefit. Due to the known risks, we advise against using rituximab as an ALS treatment.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2023)

Article Clinical Neurology

ALSUntangled # 69: astaxanthin

Timothy Fullam, Carmel Armon, Paul Barkhaus, Benjamin Barnes, Morgan Beauchamp, Michael Benatar, Tulio Bertorini, Robert Bowser, Mark Bromberg, Javier Mascias Cadavid, Gregory T. Carter, Mazen Dimachkie, Dave Ennist, Eva L. Feldman, Terry Heiman-Patterson, Sartaj Jhooty, Isaac Lund, Christopher Mcdermott, Gary Pattee, Dylan Ratner, Paul Wicks, Richard Bedlack

Summary: ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review astaxanthin which has plausible mechanisms for slowing ALS progression including antioxidant, anti-inflammatory, and anti-apoptotic effects. While there are no ALS-specific pre-clinical studies, one verified ALS reversal occurred in a person using a combination of alternative therapies which included astaxanthin. There have been no trials of astaxanthin in people living with ALS. Natural astaxanthin appears to be safe and inexpensive. Based on the above information, we support further pre-clinical and/or clinical trials of astaxanthin in disease models and PALS, respectively, to further elucidate efficacy.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2023)

Article Clinical Neurology

ALSUntangled #68: ozone therapy

Yuyao Sun, Paul Barkhaus, Benjamin Barnes, Morgan Beauchamp, Michael Benatar, Tulio Bertorini, Mark Bromberg, Gregory T. T. Carter, Jesse Crayle, Merit Cudkowicz, Mazen Dimachkie, Eva L. L. Feldman, Timothy Fullam, Terry Heiman-Patterson, Sartaj Jhooty, Isaac Lund, Christopher Mcdermott, Gary Pattee, Kaitlyn Pierce, Dylan Ratner, Paul Wicks, Richard Bedlack

Summary: ALSUntangled reviews the use of ozone therapy in ALS patients, as it has potential mechanisms to slow down ALS progression. Although a non-peer-reviewed report suggests that ozone treatment may slow down ALS progression in a mouse model, there are no clinical trials using ozone in PALS. One verified case of ALS reversal was observed with a combination of alternative treatments including ozone. However, potential serious side effects associated with ozone therapy need to be further investigated before recommending it as a treatment for PALS.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2023)

Article Clinical Neurology

A qualitative evaluation of the revised amyotrophic lateral sclerosis functional rating scale (ALSFRS-R) by the patient community: a web-based cross-sectional survey

Danielle Boyce, Michael Robinson, Jesse M. Cedarbaum, Lisa M. Shank, Christopher J. McDermott, Ruben P. A. van Eijk

Summary: This study aims to identify potential limitations of the ALSFRS-R from the perspective of people living with ALS and their caregivers. The results show that many participants expressed concerns about certain items, believing that they do not accurately reflect their abilities. Therefore, it is recommended to revise the ALSFRS-R based on co-development with patients and caregivers, or consider using alternative assessment methods.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2023)

Article Clinical Neurology

Diagnostic delay in amyotrophic lateral sclerosis

Kelly G. Gwathmey, Philippe Corcia, Chris J. McDermott, Angela Genge, Stefan Sennfalt, Mamede de Carvalho, Caroline Ingre

Summary: ALS is a fatal neurodegenerative disease with a long delay in diagnosis. This delay is influenced by lack of recognition and misdiagnosis by general practitioners, as well as patient factors such as illness behavior and site of symptom onset.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Review Health Care Sciences & Services

Factors influencing decisions people with motor neuron disease make about gastrostomy placement and ventilation: A qualitative evidence synthesis

Sean White, Alicia O'Cathain, Vanessa Halliday, Liz Croot, Christopher. J. J. McDermott

Summary: This study aims to understand how individual, clinical team, and organizational factors influence motor neuron disease patients' decisions about gastrostomy and ventilation interventions. The findings show that these decisions are emotionally driven and involve interactions with healthcare professionals and caregivers. The attitudes of healthcare professionals can affect patients' perceived agency over decisions. Patients who agree to interventions reach a tipping point where they accept the need for change.

HEALTH EXPECTATIONS (2023)

Article Clinical Neurology

Development and Evaluation of a Simulation-Based Algorithm to Optimize the Planning of Interim Analyses for Clinical Trials in ALS

Jordi W. J. van Unnik, Stavros Nikolakopoulos, Marinus J. C. Eijkemans, Jesus Gonzalez-Bermejo, Gaelle Bruneteau, Capucine H. Morelot-Panzini, Leonard E. van den Berg, Merit J. Cudkowicz, Christopher McDermott, Thomas Similowski, Ruben P. A. van Eijk, DiPALS, RespiStimALS, Ceftriaxone Study Grp

Summary: In this study, an algorithm was developed to optimize interim analysis plans for ALS clinical trials, using prior knowledge and drug-specific information to improve efficiency and minimize risks to patients.

NEUROLOGY (2023)

Article Medicine, Research & Experimental

Digital peer-to-peer support programme for informal caregivers of people living with motor neuron disease: study protocol for a multi-centre parallel group, single-blinded (outcome assessor) randomised controlled superiority trial

Louise Rose, Thilipan Thaventhiran, Esther Hobson, Rebecca Rogers, Kirsty James, Petrina Chu, Ben Carter, Christina Faull, Sian Saha, Jeong Su Lee, Georgios Kaltsakas, Christopher McDermott, Michelle Ramsay

Summary: This study aims to evaluate the efficacy of a virtual peer support programme in improving the psychological well-being and caregiving outcomes of family caregivers of individuals with motor neurone disease. Informal caregivers will be randomly assigned to either a 12-week virtual peer support programme or usual care. The primary outcome measure is the Hospital Anxiety and Depression Scale assessed at 12 weeks.

TRIALS (2023)

Review Clinical Neurology

Nutritional and metabolic factors in amyotrophic lateral sclerosis

Albert Ludolph, Luc Dupuis, Edward Kasarskis, Frederik Steyn, Shyuan Ngo, Christopher McDermott

Summary: Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease with non-motor symptoms. Nutritional status and metabolic balance have been found to contribute to faster disease progression and earlier death. Cellular changes, including mitochondrial dysfunction, are also shown to contribute to bioenergetic failure in ALS. Modifying energy balance in ALS shows potential as a treatment option and multiple clinical trials are underway.

NATURE REVIEWS NEUROLOGY (2023)

Article Nutrition & Dietetics

A critical view of the use of predictive energy equations for the identification of hypermetabolism in motor neuron disease: A pilot study

Sarah Roscoe, Ellie Skinner, Elaine Kabucho Kibirige, Charmaine Childs, C. Elizabeth Weekes, Stephen Wootton, Scott Allen, Christopher McDermott, Theocharis Stavroulakis

Summary: People with motor neuron disease often struggle to consume enough calories, leading to malnutrition and weight loss. Energy prediction equations are not accurate in estimating resting energy expenditure and metabolic index at an individual level.

CLINICAL NUTRITION ESPEN (2023)

Article Medicine, Research & Experimental

Acceptance and Commitment Therapy for people living with motor neuron disease: an uncontrolled feasibility study

Rebecca Gould, Charlotte K. Rawlinson, Ben Thompson, Kirsty Weeks, Rebecca Gossage-Worrall, Hannah A. Cantrill, Marc Serfaty, Christopher Graham, Lance H. McCracken, David White, Robert Howard, Matt Bursnall, Mike Bradburn, Ammar Al-Chalabi, Richard Orrell, Suresh Chhetri, Rupert Noad, Aleksandar Radunovic, Tim J. Williams, Carolyn J. Young, David Dick, Vanessa Lawrence, Laura Goldstein, Tracey Young, John Ealing, Hamish McLeod, Nicola Williams, Helen Weatherly, Richard Cave, Theresa Chiwera, Francesco Pagnini, Cindy Cooper, Pamela Shaw, Christopher McDermott, COMMEND Collaboration Group

Summary: This study examined the feasibility and acceptability of Acceptance and Commitment Therapy (ACT) for improving the psychological health of people living with Motor Neuron Disease (MND). The results showed that ACT may have some positive effects on the psychological health of the participants, but further research with a larger sample size is needed for confirmation.

PILOT AND FEASIBILITY STUDIES (2023)

Review Clinical Neurology

ALSUntangled #72: Insulin

Andrew Brown, Carmel Armon, Paul Barkhaus, Morgan Beauchamp, Tulio Bertorini, Mark Bromberg, Javier Mascias Cadavid, Gregory T. Carter, Jesse Crayle, Eva L. Feldman, Terry Heiman-Patterson, Sartaj Jhooty, Alexandra Linares, Xiaoyan Li, Elise Mallon, Christopher Mcdermott, Tasnim Mushannen, George Nathaniel, Gary Pattee, Kaitlyn Pierce, Ari Rappoport, Dylan Ratner, Lenka Slactova, Paul Wicks, Richard Bedlack

Summary: ALSUntangled evaluates alternative and off-label treatments for amyotrophic lateral sclerosis (ALS), including insulin. While insulin has a plausible mechanism for slowing ALS progression, limited pre-clinical studies and no trials in patients have been conducted. Moreover, insulin use in patients without metabolic needs may result in serious and potentially lethal side effects. Therefore, insulin treatment to slow ALS progression cannot be endorsed at this time.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2023)

No Data Available